Dr. Reddy's GAAP EPS of $0.06, revenue of $853M beats by $7.59M
Seeking Alpha ·
Dr. Reddy's press release ( RDY ): Q1 GAAP EPS of $0.06. Revenue of $853M (-5.5% Y/Y) beats by $7.59M . Operating Working Capital: As on 30th June 2026 at ₹143.5 billion. Capital Expenditure: Q1FY27 at ₹3.1 billion. Cash Flow (before acquisition related payout): Q1FY27
AI 시장 분석
Dr. Reddy's (RDY) reported Q1 GAAP EPS of $0.06 and revenue of $853 million, beating market estimates by $7.59 million. Although revenue decreased by 5.5% year-over-year, the better-than-expected earnings partially alleviated market concerns. As of the end of June, working capital stood at 143.5 billion rupees and capital expenditures at 3.1 billion rupees. Investors should closely monitor earnings improvement momentum and future cash flow trends.
상승 영향
- Biotechnology — Reported revenue of $853 million, beating estimates and providing positive earnings sentiment across the pharmaceutical and biotech sector.
하락 영향
- Biotechnology — Revenue decreased by 5.5% year-over-year, leaving concerns about a slowdown in growth and acting as a limiting factor for stock price upside momentum.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 50% · Bearish (Short) 50%
463 participants
Related News
- EasyJet slides on report of EU airline ownership rules review
- Nestlé close to Perrier unit stake sale at about €5b valuation - FT
- Apple working to release several new Macs, including MacBook Pro, MacBook Neo: report
- RPM International jumps on Q4 results beat
- First Financial projects 3Q net interest margin of 3.96% to 4.01% while outlining $208M Finward deal
- Lockheed Martin highlights autonomous aircraft testing, Sikorsky partnership
